

TLCR

Translational Lung Cancer Research

AN OPEN ACCESS JOURNAL FOCUSING ON CLOSING THE GAP BETWEEN "BENCH AND BEDSIDE"

Annual Report 2020

Editorial Office Email: editor@tlcr.org





Outline of the Report

- 1. Basic Information
- 2. Honorary Editors-in-Chief
- 3. Editors-in-Chief
- 4. Editorial Board Members
- 5. Publication: Number, Article Types, Internationality
- 6. Monthly Retrievals in PubMed (2015-2020)
- 7. Journal Impact Factor
- 8. Website Visits
- 9. Most Cited Articles in 2020
- 10. Special Series Published in 2020
- 11. Upcoming Special Series in 2021
- 12. Introduction of the Publisher AME






1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- Impact Factor: 5.132
- Indexed by Science Citation Index Expanded (SCIE), PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases, MDlinx
- Published quarterly (Mar. 2012 Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), and monthly (Jan. 2021 -)
- The first international journal focusing on closing the gap between "Bench and Bedside" in lung cancer and related thoracic diseases.









1. Basic Information

TLCR is the official publication of:

- General Hospital of Eastern Theater Command, Nanjing, China
- Society for Translational Medicine(STM), Hong Kong

TLCR is endorsed by:

- Spanish Lung Cancer Group (SLCG)
- Bonnie J. Addario Lung Cancer Foundation (ALCF)
- Brazilian Society of Thoracic Surgery (SBCT)





2. Honorary Editors-in-Chief



Fred R. Hirsch, MD, PhD Center for Thoracic Oncology, Tisch Cancer Institute at Mount Sinai, USA



Yi-Long Wu Guangdong General Hospital & Guangdong Academy of Medical Sciences, China





3. Editors-in-Chief



Yong Song, MD, PhD General Hospital of Eastern Theater Command, China



Caicun Zhou, MD, PhD Shanghai Pulmonary Hospital, China




Rafael Rosell, MD,PhD Dexeus University Institute, Spain





4. Editorial Board Members




135 in totality, including:

Two Honorary Editors-in-Chief
Three Editors-in-Chief
Four Associate Editors-in-Chief
One Editor Emeritus
Two Associate Editor
123 Editorial Board Members





5. Publication: Number




Till Dec 31, 2020, totally **1276** articles were published in TLCR.

The number of publication was increased from 2012-2014, yet it has kept a stability between 2014 and 2017, and has an obvious growth in 2020.





5. Publication: Diverse Article Types




TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Original Article, Review Article and Editorial.





5. Publication: Internationality




In total, **256** Corresponding Authors from **25** countries and regions contributed to TLCR in 2020, with the majority from **China and USA**.





6. Monthly Retrievals in PubMed (2015-2020)



This year, retrieval number of TLCR in PMC has reached up to a total of **833,627** times.



Source: PubMed Central




7. Journal Impact Factor

2019 Journal Impact Factor & percentile rank in category for: Translational Lung Cancer Research



2019 Journal Impact Factor





Source: Web of Science Core Collection



8. Website Visits	Country	Sessions	% Sessions
	1. 📕 United States	64,903	30.15%
	2. 🞽 China	40,253	18.70%
	3. 💶 India	12,794	5.94%
	4. 🖲 Japan	12,200	5.67%
	5. 🔠 United Kingdom	9,897	4.60%
Trank Cost	6. 😻 South Korea	6,397	2.97%
	7. Il Italy	5,972	2.77%
the second second	8. 🔛 Australia	5,582	2.59%
	9. 🚺 Canada	5,094	2.37%
64,903	10. 💻 Germany	4,724	2.19%

According to the data collected from Google Analytics, there are altogether **144,474** users and **512,594** pageviews in 2020. Readers who visited TLCR website form diverse countries, with the majority from United States, followed by China, India, Japan and United Kingdom.



Source: Google Analytics



9. Most Cited Articles in 2020

Corresponding Author	Article Title
Shaker A. Mousa	Non-small cell lung cancer: current treatment and future advances
Patricia M. de Groot	The epidemiology of lung cancer
Brett G.M. Hughes	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Jeryl Villadolid	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Nicky D'Haene	Methods of measurement for tumor mutational burden in tumor tissue
Farhad Islami	Global trends of lung cancer mortality and smoking prevalence
Fabrice Barlesi	The clinical utility of tumor mutational burden in non-small cell lung cancer
Ming-Sound Tsao	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Takashi Kohno	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Albrecht Stenzinger	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians



Source: Web of Science Core Collection



> "Mesothelioma: What We know and What We Do Not Know in 2020" edited by



Michele Carbone, MD, PhD University of Hawai'i Cancer Center, Honolulu, USA





"Lung Cancer Multidisciplinary Care" edited by



Emily Stone, MD, PhD St Vincent's Hospital Sydney, Kinghorn Cancer Centre, University of Sydney, Sydney, Australia





Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting" edited by



Sanja Dacic, MD, PhD University of Pittsburgh Medical Center, Pittsburgh, USA





"New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies" edited by



Helmut Popper, MD Medical University of Graz, Graz, Austria





* "Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions" edited by



Silvia Novello, MD, PhD University of Turin, San Luigi Hospital, Orbassano, Italy



Francesco Passiglia, MD, PhD University of Turin, San Luigi Hospital, Orbassano, Italy





"Multimodal management of locally advanced N2 non-small cell lung cancer" edited by




Mariano Provencio, MD, PhD Hospital Universitario Puerta de Hierro, Madrid, Spain





"Lung cancer screening" edited by



Paul Van Schil, MD, PhD Antwerp University Hospital, Antwerp, Belgium



Annemiek Snoeckx, MD, PhD Antwerp University Hospital, Antwerp, Belgium





> "Radiotherapy in thoracic malignancies" edited by



Jacek Jassem, MD, PhD Medical University of Gdańsk, Gdańsk, Poland.



Rafal Dziadziuszko, MD, PhD Medical University of Gdańsk, Gdańsk, Poland.






"Immunotherapy in other thoracic malignancies and uncommon populations" edited by



Jordi Remon, MD Hospital HM Delfos, HM Hospitales, Barcelona, Spain



Benjamin Besse, MD, PhD Université Paris-Saclay, Villejuif, France





> "Implementation of CT-based screening of lung cancer" edited by



Witold Rzyman, MD, PhD Medical University of Gdansk, Gdańsk, Poland





"Lung Cancer & The Immune System" edited by



Daniel Steinfort, MBBS, BMedSci, FRACP, PhD University of Melbourne, Melbourne, Australia






12. Introduction of the Publisher AME

Our Publisher– AME Publishing Company www.amegroups.com

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world
- 60+ peer-reviewed journals
- 13 indexed in SCIE
- 18 indexed in PubMed/PMC/MEDLINE
- 200+ Medical Books
- 80+ Medical Books in English
- 120+ Medical Books in Chinese
- 150+ Electronic Editions





Thank You for All Your Support!

